Edition:
United Kingdom

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.38USD
20 Feb 2018
Change (% chg)

$0.02 (+1.47%)
Prev Close
$1.36
Open
$1.37
Day's High
$1.38
Day's Low
$1.36
Volume
13,258
Avg. Vol
93,694
52-wk High
$2.12
52-wk Low
$1.06

Chart for

About

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its... (more)

Overall

Beta: 0.11
Market Cap(Mil.): $145.24
Shares Outstanding(Mil.): 97.47
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Pluristem Therapeutics Says Co Sold Its Entire Holdings In CHA Biotech Co For About $10.5 Mln

* PLURISTEM THERAPEUTICS - ON JAN 8, CO SOLD ITS ENTIRE HOLDINGS IN CHA BIOTECH CO LTD, CONSISTING OF 400,368 SHARES OF CHA, FOR ABOUT $10.5 MILLION

09 Jan 2018

BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia

* PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO'S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​

09 Jan 2018

BRIEF-Pluristem enters agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD

* Pluristem enters into agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-PLURISTEM PRICES PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE

* PLURISTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE

30 Oct 2017

BRIEF-Pluristem extends trial for treatment of insufficient hematopoietic recovery

* Following approval of israel’s ministry of health, Pluristem extends its trial of plx-r18 to treat insufficient Hematopoietic recovery after bone marrow transplant and opens clinical centers in Israel

26 Oct 2017

BRIEF-Pluristem expands its reach in the treatment of impaired hematopoietic systems

* Pluristem expands its reach in the treatment of impaired hematopoietic systems with a European patent covering PLX-R18 in chemotherapy, ARS, genetic disorders and autoimmune diseases Source text for Eikon: Further company coverage:

23 Oct 2017

BRIEF-FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy

* FDA grants Pluristem Orphan Drug Designation for its PLX-R18 cell therapy as treatment for acute radiation syndrome Source text for Eikon: Further company coverage:

19 Oct 2017

BRIEF-Pluristem receives positive feedback from FDA and EMA as co prepares for Phase III trial of PLX-PAD

* Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture

26 Sep 2017

BRIEF-U.S. FDA grants fast track designation to Pluristem's PLX-PAD for treating Critical Limb Ischemia

* U.S. FDA grants fast track designation to Pluristem's PLX-PAD for the treatment of Critical Limb Ischemia (cli)

18 Sep 2017

BRIEF-Pluristem Therapeutics awarded two new patents in Hong Kong

* Awarded two new patents in Hong Kong for critical limb ischemia and muscle regeneration

13 Sep 2017

Earnings vs. Estimates